ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has announced its participation in two major healthcare conferences in September 2025.
The company will present at the Citi Biopharma Back to School Conference in Boston on September 3 at 10:30am ET, and the Morgan Stanley Global Healthcare Conference in New York on September 8 at 7:00am ET. Both presentations will be in a fireside chat format and available via webcast through ProKidney's investor relations website.
ProKidney (Nasdaq: PROK), azienda in fase clinica avanzata specializzata in terapie cellulari per la malattia renale cronica (CKD), ha annunciato la sua partecipazione a due importanti conferenze sanitarie a settembre 2025.
La societ脿 presenter脿 al Citi Biopharma Back to School Conference a Boston il 3 settembre alle 10:30 ET e al Morgan Stanley Global Healthcare Conference a New York l'8 settembre alle 7:00 ET. Entrambe le presentazioni saranno in formato fireside chat e saranno trasmesse in webcast tramite il sito delle relazioni con gli investitori di ProKidney.
ProKidney (Nasdaq: PROK), una compa帽铆a en fase cl铆nica avanzada especializada en terapias celulares para la enfermedad renal cr贸nica (CKD), ha anunciado su participaci贸n en dos importantes conferencias de salud en septiembre de 2025.
La empresa presentar谩 en el Citi Biopharma Back to School Conference en Boston el 3 de septiembre a las 10:30 ET y en el Morgan Stanley Global Healthcare Conference en Nueva York el 8 de septiembre a las 7:00 ET. Ambas presentaciones ser谩n en formato fireside chat y estar谩n disponibles por webcast a trav茅s del sitio web de relaciones con inversores de ProKidney.
ProKidney (雮橃姢雼�: PROK)電� 毵岇劚 鞁犾灔 歆堩櫂(CKD)鞚� 鞝勲鞙茧 頃橂姅 頉勱赴 鞛勳儊 雼硠鞚� 靹疙彫 旃橂鞝� 旮办梾鞙茧, 2025雲� 9鞗� 霊� 瓯挫潣 欤检殧 項姢旒�鞏� 旖橅嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 3鞚� 鞓れ爠 10:30(霃欕秬鞁滉皠)鞐� 氤挫姢韯挫棎靹� 鞐措Μ電� Citi Biopharma Back to School Conference鞕� 9鞗� 8鞚� 鞓れ爠 7:00(霃欕秬鞁滉皠)鞐� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley Global Healthcare Conference鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 霊� 氚滍憸 氇憪 韺岇澊鞏挫偓鞚措摐 毂勴姼 順曥嫕鞙茧 歆勴枆霅橂┌ ProKidney 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
ProKidney (Nasdaq: PROK), une soci茅t茅 en phase clinique avanc茅e sp茅cialis茅e dans les th茅rapies cellulaires pour la maladie r茅nale chronique (CKD), a annonc茅 sa participation 脿 deux grandes conf茅rences de sant茅 en septembre 2025.
La soci茅t茅 interviendra au Citi Biopharma Back to School Conference 脿 Boston le 3 septembre 脿 10h30 ET, et au Morgan Stanley Global Healthcare Conference 脿 New York le 8 septembre 脿 7h00 ET. Les deux pr茅sentations se d茅rouleront sous forme de fireside chat et seront diffus茅es en webcast via le site des relations investisseurs de ProKidney.
ProKidney (Nasdaq: PROK), ein sp盲tklinisches Unternehmen f眉r zellul盲re Therapien mit Schwerpunkt auf chronischer Nierenerkrankung (CKD), hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird am Citi Biopharma Back to School Conference in Boston am 3. September um 10:30 Uhr ET und am Morgan Stanley Global Healthcare Conference in New York am 8. September um 07:00 Uhr ET pr盲sentieren. Beide Vortr盲ge finden im Fireside-Chat-Format statt und werden per Webcast 眉ber die Investor-Relations-Website von ProKidney verf眉gbar sein.
- None.
- None.
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)听(鈥淧roKidney鈥� or the 鈥淐ompany"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
| Citi Biopharma Back to School Conference (Boston) | |
| Date: | Wednesday, September 3, 2025 |
| Time: | 10:30am ET |
| Format: | Fireside Chat |
| Webcast: | |
| Morgan Stanley Global Healthcare Conference (New York) | |
| Date: | Monday, September 8, 2025 |
| Time: | 7:00am ET |
| Format: | Fireside Chat |
| Webcast: | |
| 听 | 听 |
The live webcasts of the fireside chats will be accessible through the 鈥淓vents鈥� section of the Investor Relations tab within ProKidney鈥檚 website at . Investors interested in one-on-one meetings should contact their banking representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney鈥檚 lead product candidate, rilparencel (also known as REACT庐), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit听.
Investor Contacts:
ProKidney
Ethan Holdaway
LifeSci Advisors, LLC
Daniel Ferry
FAQ
When is ProKidney (PROK) presenting at the Citi Biopharma Conference 2025?
When is ProKidney's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access ProKidney's (PROK) conference presentations?
What is ProKidney's (PROK) main focus as a company?
